Keros Therapeutics initiated with a Not Rated at Goldman Sachs

Goldman Sachs analyst Corinne Johnson initiated coverage of Keros Therapeutics with a Not Rated and no price target. While Kros is developing drugs in competitive indications, including lower-risk myelodysplastic syndrome, obesity, and pulmonary arterial hypertension, there is potential for these programs to demonstrate a best-in-class profile over time, the analyst tells investors in a research note.